In this article, we will present the 10 best stocks to invest in according to the billionaire biotech hedge fund manager Joe Edelman. Click to skip ahead...
Keep Reading →
December 19 - Hedge Funds, News - Comments
In this article we present the list of Top 10 Healthcare Stocks To Buy for the Future. Click to skip ahead and see the Top 5 Healthcare Stocks for the...
Keep Reading →
November 29 - Hedge Fund Analysis, Hedge Funds, News - Comments
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings...
Keep Reading →
September 28 - Hedge Funds, News - Comments
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (...
Keep Reading →
July 20 - Hedge Funds, News - Comments
In this article you are going to find out whether hedge funds think Cytokinetics, Inc. (NASDAQ:CYTK) is a good investment right now. We like to check...
Keep Reading →
June 16 - Hedge Funds, News - Comments
We at Insider Monkey have gone over 752 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the...
Keep Reading →
December 10 - Hedge Funds, News - Comments
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and...
Keep Reading →
November 1 - Hedge Funds, News - Comments
Balyasny Gains in First Half After Losses Prompted Reorganization in 2018 (Reuters) BOSTON (Reuters) – Balyasny Asset Management, a Chicago-based...
Keep Reading →
July 15 - Hedge Funds, Insider Trading - Comments
Hedge fund interest in Cytokinetics, Inc. (NASDAQ:CYTK) shares was flat at the end of last quarter and it wasn’t that high to begin with. This is...
Keep Reading →
June 27 - Hedge Funds, News - Comments
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment...
Keep Reading →
December 22 - Hedge Funds, News - Comments
Cytokinetics Inc (NASDAQ:CYTK): Mark Lampert’s Biotechnology Value Fund LP filed an amended 13D. You can check out Biotechnology Value Fund LP...
Keep Reading →
December 1 - Hedge Funds - Comments
You can access the original SEC filing by clicking here. Ownership Summary Table Page 1 of 13 – SEC Filing UNITED STATES SECURITIES AND EXCHANGE...
Keep Reading →
May 15 - Hedge Funds - Comments
1. US Stock Market: “U.S. stocks retreated on Tuesday as a spate of tepid corporate earnings weighed on the broader market. The Dow Jones...
Keep Reading →
April 18 - Commodities, Gold, Market Movers, News, Tech - Comments
Looking for high-potential stocks? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what...
Keep Reading →
December 9 - Hedge Funds, News - Comments
Mark Lampert‘s Biotechnology Value Fund has filed a Form 13G on Cytokinetics, Inc. (NASDAQ:CYTK), one of its top-10 holdings at the end of 2015...
Keep Reading →
March 6 - Hedge Funds, News - Comments
Before we spend many hours researching a company, we’d like to analyze what hedge funds and billionaire investors think of the stock first. We would...
Keep Reading →
November 26 - Hedge Funds, News - Comments
Below is the Cytokinetics, Inc. (NASDAQ:CYTK) conference call transcript regarding the expansion of collaboration agreement with Astellas held on Monday...
Keep Reading →
January 9 - Earnings Report, News - Comments
In another round of filings with the Securities and Exchange Commission, Steven Cohen and his fund, SAC Capital Advisors, have disclosed 4 new moves:...
Keep Reading →
April 9 - Hedge Funds, News - Comments
Mark Lampert, the founder and manager of Biotechnology Value Fund, is bullish on Cytokinetics, Inc. (NASDAQ:CYTK). According to a recent filing with...
Keep Reading →
March 26 - Hedge Funds, News - Comments
Is BioDelivery Sciences International, Inc. (NASDAQ:BDSI) a good investment? At the moment, there are many indicators market participants can use to...
Keep Reading →
September 17 - News - Comments
Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) a good investment? Now, according to many investors, hedge funds are assumed to be overrated, outdated investment...
Keep Reading →
September 17 - News - Comments
Just after the successful acquisition of Onyx Pharmaceuticals and positive results on AMG-145, a cholesterol-lowering experimental drug, Amgen, Inc...
Keep Reading →
September 11 - News - Comments
Before the market opened last Tuesday, Cytokinetics, Inc. (NASDAQ:CYTK) and Amgen, Inc. (NASDAQ:AMGN) scrambled to spin the results of their Phase 2...
Keep Reading →
September 10 - News - Comments
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into...
Keep Reading →
September 9 - News - Comments
College football arrived in a big way over the past week or so, with plenty of big plays already. Health-care stocks had their fair share of big plays...
Keep Reading →
September 7 - News - Comments
Should Pain Therapeutics, Inc. (NASDAQ:PTIE) investors track the following data? In the eyes of many investors, hedge funds are viewed as overrated,...
Keep Reading →
September 6 - News - Comments
Is ArQule, Inc. (NASDAQ:ARQL) a good investment? In the 21st century investor’s toolkit, there are many metrics shareholders can use to monitor stocks...
Keep Reading →
September 3 - News - Comments
“Bubble” can be a provocative word in investing circles. Think of all that comes to mind when you hear it — perhaps other words like...
Keep Reading →
August 27 - News - Comments
What’s a smart Cytokinetics, Inc. (NASDAQ:CYTK) investor to do? In the eyes of many of your peers, hedge funds are seen as useless, old investment...
Keep Reading →
August 22 - News - Comments
Healthcare is the most happening industry these days with new drugs on the line and investors injecting cash into companies with greater speculative growth...
Keep Reading →
August 3 - News - Comments
Small cap stocks are a bit riskier, but offer more growth than the stable large cap ones. The biotech sector in U.S. has a number of small cap stocks...
Keep Reading →
July 17 - News - Comments
Only a handful of stocks have gained 200% in 2013, and five of those stocks are in the biotechnology industry. Perhaps you already own one, or maybe...
Keep Reading →
July 12 - News - Comments
Is OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) a cheap investment today? Money managers are getting more bullish. The number of long hedge fund bets improved...
Keep Reading →
July 8 - News - Comments
Cytokinetics, Inc. (NASDAQ:CYTK) was in 8 hedge funds’ portfolio at the end of March. CYTK shareholders have witnessed an increase in support from...
Keep Reading →
June 24 - News - Comments
Is Cytokinetics, Inc. (NASDAQ:CYTK) the right pick for your portfolio? Prominent investors are in a bullish mood. The number of bullish hedge fund bets...
Keep Reading →
June 17 - News - Comments
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was in 12 hedge funds’ portfolio at the end of March. FOLD shareholders have witnessed an increase in enthusiasm...
Keep Reading →
June 14 - News - Comments
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) shareholders have witnessed a decrease in hedge fund sentiment of late; stagnant interest is a...
Keep Reading →
June 13 - News - Comments
Is Pain Therapeutics, Inc. (NASDAQ:PTIE) a buy, sell, or hold? The smart money is in a bearish mood. The number of long hedge fund positions were trimmed...
Keep Reading →
June 10 - News - Comments
A failing heart is a lot like a glass Heinz Ketchup bottle. Squeezing the bottle isn’t very efficient, so you smack that strategically placed ...
Keep Reading →
April 29 - News - Comments
Cytokinetics, Inc. (NASDAQ:CYTK) has seen a decrease in hedge fund interest in recent months. In today’s marketplace, there are a multitude of indicators...
Keep Reading →
April 15 - News - Comments
Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) a marvelous investment today? Money managers are becoming less confident. The number of bullish hedge fund...
Keep Reading →
April 13 - News - Comments
Is Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) a buy, sell, or hold? The best stock pickers are taking a bearish view. The number of long hedge fund positions...
Keep Reading →
April 12 - News - Comments
Don’t settle for ordinary quarterly reports. Every week, I take a look at three companies that beat market expectations, since I believe that it...
Keep Reading →
February 11 - News - Comments